title: One-year real-life efficacy of sitagliptin revealed importance of concomitant pioglitazone use in Japanese patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  Dipeptidyl-peptidase 4 inhibitors have become one of the most popular antidiabetic drugs. However, what kind of combinations with other drugs were advantageous was not known. Here, we tried to elucidate it in a real-life clinical setting.
  
  
  METHODS
  We retrospectively studied efficacies of sitagliptin in 87 Japanese patients with type 2 diabetes mellitus for 52 weeks. We divided subjects into excellent, effective and unresponsive subgroups according to glycemic responses to sitagliptin.
  
  
  RESULTS
  In the excellent and effective groups the minimum HbA1c values were attained at 16 weeks while HbA1c levels in the unresponsive group kept increasing during the study period. There was a significant difference in the baseline HbA1c values between the excellent and unresponsive groups (p=0.02). Interestingly, the mean doses of pioglitazone were highest in the excellent group and lowest in the unresponsive group (p=0.02). When we compared the effective and unresponsive groups, the mean doses of sulfonylureas were constantly higher in the effective group than in the unresponsive group (p=0.05).
  
  
  CONCLUSIONS
  These data suggest that the baseline HbA1c value can be a factor that predicts the extent of HbA1c reduction and reveal a possibility that the concomitant use of pioglitazone augments glycemic responsiveness to sitagliptin.
authors: Department of Internal Medicine, School of Medicine, Teikyo University, Tokyo 173-8605, Japan.
authors: Ayako
authors: A
authors: Suzuki
authors: Nakayuki
authors: N
authors: Yoshimura
authors: Yamato
authors: Y
authors: Mashimo
authors: Maiko
authors: M
authors: Numakura
authors: Yuko
authors: Y
authors: Fujimaki
authors: Tomomi
authors: T
authors: Maeda
authors: Toshio
authors: T
authors: Ishikawa
authors: Shin
authors: S
authors: Fujimori
authors: Kazuhiro
authors: K
authors: Eto
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D044466:Asian People / Q000706:statistics & numerical data*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D000077205:Pioglitazone; D011719:Pyrazines / Q000627:therapeutic use*; D012189:Retrospective Studies; D000068900:Sitagliptin Phosphate; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D000077205:Pioglitazone; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D045162:Thiazolidinediones; D014230:Triazoles; C517652:hemoglobin A1c protein, human
keywords: Concomitant drug; Dipeptidyl-peptidase 4 inhibitor; Pioglitazone; Sitagliptin